piribedil has been researched along with guanosine 5'-o-(3-thiotriphosphate) in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Audinot, V; Boutin, JA; Brocco, M; Carr, C; Cussac, D; Duqueyroix, D; Gobert, A; Lejeune, F; Millan, MJ; Milligan, G; Newman-Tancredi, A; Nicolas, JP; Rivet, JM | 1 |
1 other study(ies) available for piribedil and guanosine 5'-o-(3-thiotriphosphate)
| Article | Year |
|---|---|
Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Agonists; Animals; Antiparkinson Agents; Binding, Competitive; CHO Cells; Cricetinae; Dose-Response Relationship, Drug; Frontal Lobe; GTP Phosphohydrolases; GTP-Binding Protein alpha Subunits, Gi-Go; Guanosine 5'-O-(3-Thiotriphosphate); Hippocampus; Humans; Locus Coeruleus; Male; Mitogen-Activated Protein Kinases; Neurons; Norepinephrine; Phosphatidylinositols; Phosphorylation; Piribedil; Rats; Rats, Wistar; Receptors, Adrenergic, alpha-2; Recombinant Fusion Proteins; Serotonin | 2001 |